Reviewing TScan Therapeutics (NASDAQ:TCRX) and Urogen Pharma (NASDAQ:URGN)

TScan Therapeutics (NASDAQ:TCRX) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Analyst Recommendations

This is a summary of recent ratings and target prices for TScan Therapeutics and Urogen Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1	2	4	0	2.43
Urogen Pharma	1	1	7	0	2.67

TScan Therapeutics presently has a consensus target price of $6.60, suggesting a potential upside of 478.95%. Urogen Pharma has a consensus target price of $33.00, suggesting a potential upside of 65.00%. Given TScan Therapeutics’ higher probable upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Urogen Pharma.

Earnings & Valuation

This table compares TScan Therapeutics and Urogen Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$2.82 million	22.94	-$127.50 million	($1.12)	-1.02
Urogen Pharma	$90.40 million	10.36	-$126.87 million	($3.46)	-5.78

Urogen Pharma has higher revenue and earnings than TScan Therapeutics. Urogen Pharma is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TScan Therapeutics and Urogen Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,692.96%	-73.33%	-44.76%
Urogen Pharma	-170.59%	N/A	-71.04%

Insider & Institutional Ownership

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 4.4% of TScan Therapeutics shares are held by insiders. Comparatively, 4.7% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

TScan Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Summary

Urogen Pharma beats TScan Therapeutics on 9 of the 14 factors compared between the two stocks.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.